Matoke Holdings’ Reactive Oxygen® technology was hailed in the House of Lords yesterday as an innovative product with the potential to transform wound care in the NHS. In a debate on improving NHS standards in wound treatment, Lord Colwyn outlined the efficacy of Reactive Oxygen® in treating hospital spread superbugs such as MRSA.
Reactive Oxygen’s use in tackling the global threat of antimicrobial resistance was also outlined, as Matoke looks to fast track the technology through the pharmaceutical regulatory process and produce a new generation of novel antimicrobials.
Health Minister Lord O’Shaughnessy welcomed the development of Reactive Oxygen® and looked forward to the results of further research demonstrating the potential of the cutting edge technology.
Reactive Oxygen is a British-led innovation that offers a breakthrough in medical research. In both laboratory and clinical tests, Reactive Oxygen has been proven an effective treatment of Gram-positive, Gram-negative, multi-resistant and pan-resistant bacteria. Studies are now being undertaken to prove its efficacy against the 12 priority superbugs highlighted by the World Health Organization.
Ian Staples, Chief Executive of Matoke Holdings said:
“The Government’s focus in improving wound treatment in the NHS is most welcome, especially as the threat of antimicrobial resistance continues to escalate. Policy makers must work with researchers to ensure innovative treatments can reach the NHS and meet this highly important medical need”.
About Matoke Holdings
Matoke Holdings Ltd (MHL) is a British biotechnology development SME developing Reactive Oxygen technology as a novel antimicrobial which has been hailed as potentially the biggest breakthrough since the discovery of penicillin.
With the World Health Organisation predicating millions will die due to global antimicrobial resistance (AMR), Reactive Oxygen® technology is a solution to meet the global AMR threat, improve patient outcomes and lives. To date, in tests in the laboratory and on patients, no Gram-positive and Gram-negative bacteria, including all multi-resistant strains have survived the present of Reactive Oxygen technology.
In partnership with world-leading researchers at British universities and teaching hospitals, MHL has developed a wide application format that takes the Reactive Oxygen technology platform into the heart of where antibiotics are increasingly failing.
NOTES TO THE EDITOR:
For further information, please contact Edward Jones on 020 7340 1150 or at email@example.com.
You can find more information about Matoke Holdings on their website at com.
A video recording of the Lords session can be found here: http://parliamentlive.tv/Event/Index/b557e444-8aed-40a5-9ffd-2638e4acbe39?agenda=True .